The papers in this special issue were first given at a conference in Toronto, Canada, in April 2004 entitled ‘Genomics, Genetics, and Society: Bridging the Disciplinary Divides’. The papers fall into four intersecting themes. (1) The introduction of genetic and genomic technologies into communities. (2) Governance, the morals of scientific discourse and policy making. (3) What is a gene? (4) Public knowledge, public trust and improved dialogue between the public and scientists.

1.
Snow CP: The Two Cultures and the Scientific Revolution. New York, Cambridge University Press, 1959.
2.
Snow CP: Two Cultures: And a Second Look. Cambridge, Cambridge University Press, 1964.
3.
Wynne B: Public uptake of science: a case for institutional reflexivity. Public Understand Sci 1993;2:321–337.
4.
Irwin A, Wynne B: Misunderstanding Science: The Public Reconstruction of Science and Technology. Cambridge, Cambridge University Press, 1996.
5.
Kerr A, Cunningham-Burley S, Amos A: The new genetics and health: mobilizing lay expertise. Public Understand Sci 1998;7:41–60.
6.
MacIntyre S: The public understanding of science or the scientific understanding of the public? A review of the social context of the ‘new genetics’. Public Understand Sci 1995;4:223–232.
7.
Healy D: Let Them Eat Prozac. Toronto, James Lorimer, 2003.
8.
Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 2004;172:1297–1301.
9.
Fletcher SW, Colditz GA: Failure of estrogen plus progestin therapy for prevention. JAMA 2002;288:321–333.
10.
Davis D: Groups,communities and contested identities in genetic research. Hastings Cent Rep 2000;30:38–45.
11.
Weijer C: The need to protect the community in research. Camb Q Healthc Ethics 1999;8:501–513.
12.
Burgess MM, Brunger F: Negotiating collective acceptability of health research; in McDonald M (ed): Governance of Health Research Involving Human Subjects. Ottawa, Law Commission of Canada, 2000, pp 117–151.
13.
Burke W, Pinsky LE, Press NA: Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Gen 2001;106:233–240.
14.
Cox SM, Starzomski RC: Genes and geneticization? The social construction of autosomal dominant polycystic kidney disease. New Genet Soc 2004;23:137–166.
15.
Lock M, Lloyd S, Prest J: Genetic susceptibility and Alzheimer’s disease: the penetrance and uptake of genetic knowledge; in Leibing A, Cohen L (eds): Anthropological Approaches to Alzheimer’s Disease. New Jersey, Rutgers University Press, in press.
16.
Rapp R: Testing Women, Testing the Fetus: The Social Impact of Amniocentesis in America. New York, Routledge, 2000.
17.
Hallowell N, Statham H, Murton F, Green J, Richards M: ‘Talking about chance’: the presentation of risk information during genetic counseling for breast and ovarian cancer. J Genet Couns 1997;6:269–286.
18.
d’Agincourt-Canning L: The effect of experiential knowledge on construction of risk perception in hereditary breast/ovarian cancer. J Genet Couns 2005;14:55–69.
19.
Cox SM, McKellin WH: ‘There’s this thing in our family’: predictive testing and the social construction of risk for Huntington disease. Sociol Health Illness 1999;21:622–646.
20.
d’Agincourt-Canning L: Experiences of genetic risk: disclosure and the gendering of responsibility. Bioethics 2001;15:231–247.
21.
Symposium on the 25th anniversary of the Asilomar conference, special issue. Perspect Biol Med 2001;44:159.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.